Literature DB >> 7686313

A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody.

S Taniguchi1, H Okamoto, M Sakamoto, M Kojima, F Tsuda, T Tanaka, E Munekata, E E Muchmore, D A Peterson, S Mishiro.   

Abstract

Hepatitis C virus persists in most infected hosts, and causes chronic hepatitis, liver cirrhosis, and/or hepatocellular carcinoma in humans. During the infection the RNA genome of hepatitis C virus undergoes frequent missense mutations at one or two "hypervariable" regions within a presumptive envelope gene (Okamoto et al., 1992, Virology 190, 894-899; Ogata et al., 1991, Proc. Natl. Acad. Sci. USA 88, 3392-3396). In the present study, we analyzed three cases of hepatitis C virus infection, two in chimpanzees and one in humans, for the antigenicity of peptides predicted from the hypervariable region of viral RNA obtained during the follow-up. Our results showed a successive appearance of hepatitis C virus mutants with antigenically distinct amino acid sequence within the domain; and the amino acid replacement was associated with an alteration of predicted local secondary structure of the epitope region. Hence, the hypervariable domain of the hepatitis C virus envelope appeared to be structurally flexible and antigenically variable, providing the virus a way to escape from host immunity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686313     DOI: 10.1006/viro.1993.1378

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  49 in total

Review 1.  Immunopathogenesis of viral hepatitis.

Authors:  M U Mondelli
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Antiviral genetic program is a new type of DNA vaccine.

Authors:  I G Sivov; A Sobolev; E I Samokhvalov; V I Sergienko
Journal:  Dokl Biochem Biophys       Date:  2001 Mar-Apr       Impact factor: 0.788

3.  Monitoring of hepatitis C virus quasispecies in chronic infection by matrix-assisted laser desorption ionization-time of flight mass spectrometry mutation detection.

Authors:  Carmen Yea; Jens Bukh; Melissa Ayers; Eve Roberts; Mel Krajden; Raymond Tellier
Journal:  J Clin Microbiol       Date:  2007-01-17       Impact factor: 5.948

Review 4.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

5.  Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.

Authors:  Dapeng Li; Markus von Schaewen; Xuesong Wang; Wanyin Tao; Yunfang Zhang; Li Li; Brigitte Heller; Gabriela Hrebikova; Qiang Deng; Alexander Ploss; Jin Zhong; Zhong Huang
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

6.  Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort.

Authors:  J McAllister; C Casino; F Davidson; J Power; E Lawlor; P L Yap; P Simmonds; D B Smith
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 7.  The quasispecies of hepatitis C virus and the host immune response.

Authors:  P Farci; J Bukh; R H Purcell
Journal:  Springer Semin Immunopathol       Date:  1997

8.  Predictors of response to interferon therapy.

Authors:  G Saracco; M Rizzetto
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

9.  Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.

Authors:  A Weiner; A L Erickson; J Kansopon; K Crawford; E Muchmore; A L Hughes; M Houghton; C M Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Characterization of hepatitis C virus quasispecies by matrix-assisted laser desorption ionization-time of flight (mass spectrometry) mutation detection.

Authors:  Melissa Ayers; Karen Siu; Eve Roberts; Alex M Garvin; Raymond Tellier
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.